Windham Capital Partners
Windham Capital Partners is a venture capital firm focused on investing in innovative HealthTech companies that are developing life-saving and game-changing technologies. The firm leverages its extensive network in the pharmaceutical, medical device, and digital health markets to build strategic relationships and support entrepreneurs in creating category-defining products. Windham Capital Partners is committed to investing in companies that address large unmet medical needs and have the potential to transform healthcare, ultimately providing significant returns to its investors.
Windham Capital Partners
500 Fifth Avenue, Ste 3600 New York, NY 10110
Portfolio
Alto Neuroscience announced $60 million in additional financing and positive results for ALTO-100 in Phase 2 study.
#HealthTech
Awarded National Cancer Institute Phase 2 Grant to advance clinical development of VGT-309 in lung cancer.
#Biotechnology
Announced $225 million Series B financing to develop a globally accessible portfolio of liquid biopsy tests.
#Diagnostics
Announced $45 million growth equity financing to increase access to evidence-based mental health services.
#Mental Health